FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third Line Treatment of Metastatic Triple-negative Breast Cancer (mTNBC).

This article summarizes the FDA review process and data supporting the approval of sacituzumab govitecan. PMID: 33168656 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33168656?dopt=Abstract

Source: Clinical Cancer Research - November 9, 2020 Category: Cancer & Oncology Authors: Wahby S, Fashoyin-Aje L, Osgood CL, Cheng J, Fiero MH, Zhang L, Tang S, Hamed SS, Song P, Charlab R, Dorff SE, Ricks TK, Barnett-Ringgold K, Dinin J, Goldberg KB, Theoret MR, Pazdur R, Amiri-Kordestani L, Beaver JA Tags: Clin Cancer Res Source Type: research